IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
three years, but can be ex tended. If the com pa nies do not re new the part ner ship, Takeda will be el i gi ble
to re ceive de clin ing tail pay ments for a pe riod of three years fol low ing 2006. Un der the agree ment,
TPNA’s 1,000-strong US sales force will co-pro mote the prod ucts and Takeda will re ceive an un dis closed
per cent age of net sales for the Kos’s (now Abbott’s) cur rent cho les terol franchise above a specific
baseline level.
Lifecycle Man age ment: Kos an nounced in July 2006 that it had sub mit ted a sup ple men tal NDA to the
US FDA, seek ing the ap proval of a com plete dos age range of Niaspan CF, a caplet for mu la tion of the
prod uct. The Niaspan CF range in cludes an op ti mized 1000mg caplet formulation.
� Central Nervous System Agents
ANPEC TAKEDA (mor phine hy dro chlo ride) was launched in Ja pan in 1991. It was co-launched with
Tanab (now Mitsubishi Tanabe Pharm), Sankyo (now Daiichi Sankyo), Shionogi and Dainippon (now
Dainippon Sumitomo, all Ja pan), which mar ket it as Anpec Tanabe, Anpec Sankyo etc. A con cen trated
high-dose ver sion of mor phine hy dro chlo ride has been filed in Ja pan by Takeda and its joint de vel op ment
part ners (with the lab o ra tory code MH 200), for the treat ment of se vere pain due to cancer.
EURODIN (estazolam), an in ter me di ate-act ing benzo diaz epine, has been mar keted world wide for the
short-term man age ment of in som nia since 1967. It was orig i nally de vel oped by the Takeda/Abbott joint
ven ture, TAP (USA), dis solved in May 2008. In 2003, estazolam was launched in Tai wan, Rus sia and Lat -
via as a treat ment for insomnia.
HIRTONIN (protirelin), a thyrotropin-re leas ing hor mone, has been on the mar ket for some years as a
di ag nos tic and ther a peu tic agent and was launched by Takeda in Ja pan as Hirtonin in 1978 as a
nootropic. In 1988, Takeda Italia launched it as a nootropic un der the name Irtonin.
MS CONTIN TAKEDA (mor phine sul fate) is a slow-re lease mor phine prod uct, orig i nally de vel oped by
Mundipharma (Swit zer land). It was li censed out to Takeda for Ja pan and launched there in 1989. It was
co-de vel oped with Tanabe (now Mitsubishi Tanabe Pharma), Sankyo (now Daiichi Sankyo), Shionogi and
Dainippon (now Dainippon Sumitomo), which co-mar ket the prod uct in Ja pan as MS Contin Tanabe,
MS Contin Sankyo etc. A high-dose con cen trated ver sion was launched in Japan in 1995.
NICHOLIN (citicoline), an oral neuroprotective is avail able in more than 70 coun tries for the treat ment
of ischemic stroke. Takeda sells the drug in Ja pan.
OPSO TAKEDA (mor phine hy dro chlo ride) is an oral for mu la tion pre-pre pared in dos age units of 5mg
and 10mg. It is in di cated for mod er ate to se vere pain in can cer, and was launched in Ja pan in 2003.
OXYCONTIN TAKEDA (oxycodone) is a re tard-film coated tab let for mu la tion used for mod er ate to se -
vere pain in var i ous types of can cer. It was launched in Ja pan in 2003.
PREPENON TAKEDA (in ject able mor phine hy dro chlo ride) was launched in Ja pan in 2001, through a
part ner ship with Terumo (Ja pan). It is in di cated for the re lief of pain in can cer pa tients. Takeda is re spon -
si ble for sales and Terumo for de vel op ment and pro duc tion. Prepenon is sold in pre-filled sy ringes, in -
creas ing con ve nience for pa tients treat ing themselves at home.
PROVIGIL (modafinil), a non-am phet amine psychostimulant for narcolepsy and id io pathic
hypersomnia. It was first launched in France in 1994 for the treat ment of narcolepsy and id io pathic
hypersomnia, and has sub se quently been launched in most mar kets world wide, in clud ing the USA, Eu -
rope, Can ada and Aus tra lia, and is await ing ap proval in Ja pan for this in di ca tion. In Au gust 2006 the US
FDA is sued a non-ap prov able let ter for Cephalon’s s NDA for the use of modafinil in the treat ment of at -
© 2009 IMS Health In cor po rated or its af fil i ates Page 45